Escitalopram effects on insula and amygdala BOLD activation during emotional processing

Area of Science:

• Neuroscience
• Psychopharmacology
• Medical Imaging

Background:

• The amygdala and insular cortex are key in processing emotional stimuli.
• Previous research showed lorazepam reduced limbic activation in healthy volunteers.
• Selective serotonin reuptake inhibitors (SSRIs) are widely used for anxiety and mood disorders.

Purpose of the Study:

• To investigate if escitalopram, a SSRI, alters limbic structure activation.
• To test the hypothesis that subchronic SSRI treatment attenuates amygdala and insula activation during emotional face processing.

Main Methods:

• A double-blind, placebo-controlled, crossover study with 13 healthy volunteers.
• 21 days of treatment with either escitalopram or placebo.
• Functional magnetic resonance imaging (fMRI) during an emotion face assessment task.

Main Results:

• Both escitalopram and placebo led to bilateral insula and amygdala activation.
• Adherent subjects showed reduced amygdala activation with escitalopram compared to placebo.
• fMRI revealed differential effects of escitalopram on amygdala response.

Conclusions:

• Provides evidence for SSRI mechanism of action via attenuation of emotion processing brain regions.
• Supports the use of fMRI with pharmacological probes to identify therapeutic effects of SSRIs.
• Suggests potential for fMRI in diagnosing and treating anxiety and mood disorders.